Zacks Investment Research upgraded shares of INFINITY PHARMA (INFI) from UNDERPERFORM to NEUTRAL on February 26, 2013, with a target price of $41.50.
Infinity Pharmaceuticals, Inc. is an innovative cancer drug discovery and development company that is seeking to leverage its strength in small molecule drug technologies to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on INFINITY PHARMA (INFI),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment